Pfizer’s RSV vaccine found effective, safe among older adults in study

(Reuters) – Pfizer Inc stated on Thursday its vaccine for Respiratory Syncytial Virus (RSV) was efficient amongst older adults in a late-stage examine and it plans to file for approval with the U.S. well being regulator within the coming months.

There are not any U.S. authorised vaccines for RSV, a standard virus that sometimes causes delicate cold-like signs however will be deadly for younger children and older adults. RSV is estimated to trigger about 14,000 annual deaths amongst older adults in the US.

Pfizer’s vaccine was 85.7% efficient amongst contributors with three or extra signs, and 66.7% for 2 or extra signs, in line with an interim evaluation carried out by an exterior information monitoring panel.

The vaccine, RSVpreF, was additionally discovered to be well-tolerated with no security issues within the examine.

Pfizer’s shot is designed to focus on two strains of the respiratory virus. The corporate has up to now enrolled about 37,000 contributors aged 60 and above in its late-stage world examine of the vaccine.

Rival Moderna additionally started a late-stage examine of its messenger RNA shot for RSV in February.

Pfizer stated it additionally plans to arrange submissions for approval of the shot to different regulatory authorities within the coming months.

(Reporting by Amruta Khandekar; Modifying by Shinjini Ganguli)